IMMUNIC, INC. (IMUX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$186.6M
Cash & Equivalents
$17.3M
Quarterly Burn Rate
32 mo
Est. Cash Runway
$201M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-01 | Phase3 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05134441 | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | PHASE3 | Active Not Recruiting | 1,121 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.